The molecular Prognostic Score (mPS) provides additional information to both the patient and the physician to help tailor medical management of patients with early stage lung adenocarcinoma histology.
No two cancers are the same, so each test report is unique to each patient.
Same Stage: Different Risk
myPlan Lung Cancer measures how fast a lung cancer tumor is growing. Fast growing tumors are more aggressive and correlated with higher risk. Tissue samples collected during surgery are used to determine the mPS and calculate the patient’s five-year survival probability. Several studies have shown that myPlan Lung Cancer is an accurate and reproducible risk assessment based on the biological nature of the patient’s tumor1,2,3.
myPlan Lung Cancer is validated in multiple peer-reviewed publications for patients with1,2,3:
- Surgically resected non-small cell lung cancer (NSCLC)
- Adenocarcinoma (all histological subtypes)
- Pathological stage IA – IIB disease
- Bueno R, et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 2015; 10:67-73.
- Rakha E, et al. Stratification of resectable lung adenocarcinoma by molecular and phatoligcal risk estimators. Eur J Cancer 2015; 51:1897-1903
- Eguchi E, et al. Validation of a cell cycle progression score for five-year mortality risk in patients with stage I lung adenocarcinoma. Presented at ASCO 2015.